Bristol-Myers Squibb Company Q3 2026 Earnings Recap

Bristol Myers Squibb’s third-quarter results were accompanied by a modest 1.4% stock gain, a roughly flat reaction. The growth portfolio advanced and management raised full-year guidance, while the transcript also highlights a busy late-stage pipeline; it provides no basis to assess how results compared with market expectations.

Key Takeaways

• Growth portfolio sales increased 12%, with management citing Reblozyl, Breyanzi, Opdualag, Qvantig and Camzyos.
• The company said it raised full-year guidance, but the excerpt does not provide the revised figures.
• Symvexis received FDA accelerated approval for multiple myeloma; BMS also reported positive Phase 3 PFS data and plans to present them at ASH in December.
• BMS cited positive results from registrational studies of admilparant, RAISE 101 and Arlocell, with regulatory discussions or further data expected.
• The company announced approximately $2.3 billion for a Houston manufacturing campus and more than $170 million for a radiopharmaceutical facility in Indiana.